Halozyme Therapeutics Q3 Adj. EPS $2.39 Beats $2.35 Estimate, Sales $492.974M Beat $491.561M Estimate
Benzinga Newsdesk 11 hours ago
NewsEarningsEarnings Beats
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.39 per share which beat the analyst consensus estimate of $2.35 by 1.27 percent. This is a 38.95 percent increase over earnings of $1.72 per share
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.39 per share which beat the analyst consensus estimate of $2.35 by 1.27 percent. This is a 38.95 percent increase over earnings of $1.72 per share from the same period last year. The company reported quarterly sales of $492.974 million which beat the analyst consensus estimate of $491.561 million by 0.29 percent. This is a 39.15 percent increase over sales of $354.264 million the same period last year.